MONDAY, 30 June

Program subject to change.

6:40 - 7:40 | EACPT early morning activities (run, walk or yoga) 

Details to be announced
EACPT2025 Chair Janne Backman, University of Helsinki, Helsinki, Finland, and
EACPT Chairperson Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands
8:20 - 9:00 | Keynote Lecture 2

Chair: Outi Lapatto-Reiniluoto, Helsinki University Hospital, Helsinki, Finland
Climate Change and its Health Dimensions
Petteri Taalas, Director General, Finnish Meteorological Institute
9:00 - 10:30 | Concurrent Sessions

Session A3: Societal perspective of pharmacotherapy
Chairs: Katri Hämeen-Anttila, University of Eastern Finland, Kuopio, Finland and Martin Fromm, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany

9:00 - 9:30Policies and strategies to enhance uptake of biosimilars
Dorthe Barthels, Amgros I/S, Copenhagen, Denmark




9:30 - 10:00Financial burden of medicines for patients
Katri Aaltonen, University of Turku, Turku, Finland




10:00 - 10:15Increasing use of gabapentinoids out of their authorised indications (Abstract O015)
Caridad Pontes, Hospital De La Santa Creu I Sant Pau - Universitat Autònoma De
Barcelona, Barcelona, Spain




10:15 - 10:30Polypharmacy in old patients before and after acute rehabilitation – an observational
study in Western Pomerania (Abstract O016)
Benedikt Eisenmann, University Greifswald, Departement of Clinical Pharmacology,
Greifswald, Germany




Session B4: Drug development beyond the era of small molecules 
Chairs: Katriina Vuolteenaho, Tampere University, Tampere, Finland and Carolina Säll, Novo Nordisk, Copenhagen, Denmark

9:00 - 9:30Reflections on two decades of oligo ADME development 
Steve Hood, GSK, Stevenage, United Kingdom




9:30 - 10:00Can we utilize a small molecule strategy when developing therapeutic peptides?
Carolina Säll, Novo Nordisk, Copenhagen, Denmark




10:00 - 10:15Relative and absolute bioavailability study of NXT007, a novel haemophilia A treatment,
confirms patient flexibility between different injection sites (Abstract O017)
Marion Anliker-Ort, F. Hoffmann-La Roche AG, Basel, Switzerland




10:15 - 10:30Ex vivo pembrolizumab pharmacology for personalized PD-1 inhibitor therapy reveals
a critical gap between receptor occupancy and T cell functionality (Abstract O018)
Judith Verdonk, Radboudumc, Nijmegen, The Netherlands




Session C4: Neurodegenerative diseases
Chairs: Mikko Airavaara, University of Helsinki, Helsinki, Finland and Dominique Deplanque, University of Lille, Lille, France

9:00 - 9:30Intra-cerebral administration of an anaerobic form of dopamine in Parkinson's disease: 
from experimental models to clinical development
David Devos, University of Lille, Lille, France                    




9:30 - 10:00Parkinson's disease subtypes - does it impact pharmacological management?
Filip Scheperjans, University of Helsinki, Helsinki, Finland




10:00 - 10:15Increased mortality in dementia patients using inhaled anticholinergics- a nationwide
register study from the Swedish registry on dementia/cognitive disorders, SveDem 
(Abstract O019)
Suzan Almayahi, Karolinska Institutet, Stockholm, Sweden




10:15 - 10:30CSF exposure of HER-096, a subcutaneously administered CDNF-peptidomimetic 
developed for Parkinson’s disease (Abstract O020)
Kira Holmström, Herantis Pharma, Espoo, Finland



10:30 - 11:00 | Refreshment Break

11:00 - 12:30 | Concurrent Sessions

Session A4: TDM: benefits and limitations
Chairs:  Erik Eliasson, Karolinska Institutet, Stockholm, Sweden and Pierre Marquet, University of Limoges, Limoges, France

11:00 - 11:30The value of mycophenolate mofetil therapeutic drug monitoring for kidney transplant patients
Pierre Marquet University of Limoges, Limoges, France

11:30 - 12:00Antimicrobial TDM in the critically ill
Jason Roberts, University of Queensland, Brisbane, Australia

12:00 - 12:15Contribution of the gut microbiome to tacrolimus metabolism – a randomized phase I
cross-over trial in healthy volunteers (Abstract O021)
Katja Susanne Gümüs, Heidelberg University Hospital, Department of Clinical Pharmacology
and Pharmacoepidemiology, Heidelberg, Germany

12:15 - 12:30Model-informed precision dosing of busulfan for children and adults undergoing allogeneic
hematopoietic stem cell transplantation: a critical evaluation (Abstract O022)
Rashudy Mahomedradja, Amsterdam UMC, Alkmaar, the Netherlands

Session B5: Addressing unmet needs
Chairs: Timo Myöhänen, University of Helsinki, Helsinki, Finland and Caridad Pontes, Universitat Autónoma de Barcelona, Barcelona, Spain

11:00 - 11:30Making rare disease treatments less rare
Tina Taube, EFPIA, Brussels, Belgium




11:30 - 12:00Model-informed drug development for rare diseases
Piet van der Graaf, University of Leiden, The Netherlands          




12:00 - 12:15GABAergic modulation in neuropathic pain patients: results of a randomized controlled trial
with the α2-subunit preferring GABA modulator, N-desmethyl-clobazam (Abstract O023)
Marie Besson, Geneva University Hospitals, Geneva, Switzerland




12:15 - 12:30Accelerating access to innovative therapies: a retrospective analysis of the EMA PRIME
program (Abstract O024)
Vanessa A. Prieto, Vall d’Hebron University Hospital (HUVH), Barcelona, Spain




Session C5: Chronic pulmonary diseases
Chairs: Jukka Mäenpää, Astra Zeneca, Gothenburg, Sweden and Clive Page, King's College London, London, United Kingdom

11:00 - 11:30Disease modifying treatments in early COPD
Rod Hughes, AstraZeneca, Cambridge, United Kingdom                                                    




11:30 - 12:00Emerging drug targets in chronic pulmonary disease
Clive Page, King's College London, London, United Kingdom




12:00 - 12:15Attitudes of patients with obstuctive pulmonary disease on the global warming impact
of inhalers (Abstract O025)
Olga Sič, Department Of Pharmacology, Toxicology And Clinical Pharmacology,
Faculty Of Medicine Novi Sad, University Of Novi Sad, Novi Sad, Serbia




12:15 - 12:30Metformin as adjuvant therapy in pulmonary fibrosis: open label, randomised clinical trial
(proof-of-concept study) (Abstract O026)
Shivom Pratap, Aiims New Delhi, New Delhi, India



12:30 - 14:00 | Lunch and Poster Viewing


13:00 - 14:00Presenters at posters P221-P245, P325-P357, P414-P429














14:00 - 15:30 pm | Concurrent Sessions

Industry Sponsored Session A5: Medbase Symposium - Decision support tools in pharmacotherapy (preliminary program)
Chairs: Maija Kaukonen, Medbase, Turku, Finland and Kari Laine, Medbase, Turku, Finland

14:00 - 14:30Decision support systems in optimizing pharmacotherapy: Evidence, challenges, and future directions
Ylva Böttiger, Linköping University, Linköping, Sweden                                                  



14:30 - 15:00Transforming care through clinical decision support – the future is here
Christoph U. Herborn, City Hospital Dessau, Dessau, Germany



15:00 - 15:15Medbase solutions for decision-making tools in pharmacotherapy
Maija Kaukonen, Medbase, Turku, Finland



15:15 - 15:30Protocol for assessing drug interaction prevalence in Estonia through digital decision support
integration (Abstract O027)
Jana Lass, Tartu University Hospital, Tartu, Estonia



Session B6: ADME biomarkers and extracellular vesicles: Phenotyping of drug metabolism, transport, and interactions
Chairs:  Anne Filppula, Åbo Akademi University, Turku, Finland and Julia Stingl, Uniklinik RWTH Aachen,  Aachen, Germany

14:00 - 14:30Application of endogenous biomarkers and liquid biopsy in patients with renal impairment
Alexandra Galetin, University of Manchester, Manchester, United Kingdom



14:30 - 15:00Phenotyping with biomarkers to model drug interactions
Julia Stingl, Uniklinik RWTH Aachen, Aachen, Germany



15:00 - 15:15Identification of endogenous substrates of ABC transporters using untargeted metabolomics (Abstract O028)
Feng Deng, University of Helsinki, Helsinki, Finland


15:15 - 15:30Intra-individual and inter-individual expression of “major” and “minor” drug metabolizing
enzymes along the length of the human intestine (Abstract O029)
Stefan Oswald, Institute of Pharmacology and Toxicology, Rostock University Medical
Center, Rostock, Germany



Session C6: Vascular diseases
Chairs: Virpi Talman, University of Turku, Turku, Finland and Gerard Rongen, Radboud University Medical Center, Nijmegen, the Netherlands

14:00 - 14:30Lipid-lowering therapies - what is on the horizon for triglycerides and Lp(a)?  
Giuseppe Danilo Norata, University of Milan, Milan, Italy



14:30 - 15:00Is there a holy grail of anticoagulation without increased bleeding?
Riitta Lassila, University of Helsinki, Helsinki, Finland



15:00 - 15:15A three-step static mechanistic approach to predicting complex interaction signals of direct
oral anticoagulants (Abstract O030)
Mostafa Schaat, University of Turku, Turku, Finland



15:15 - 15:30The association of CYP3A4, CYP3A5, ABCG2 and SLCO1B1 variants with atorvastatin-related
ADRs and therapy switching: PGx-CardioDrug data (Abstract O031)
Lana Ganoci, University of Zagreb School of Medicine, Zagreb, Croatia


15:30 - 16:00 | Refreshment Break
16:00 - 17:00 | EACPT General Assembly
Chairs: EACPT Chairperson Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands and EACPT Chairperson-elect Janne Backman, University of Helsinki, Helsinki, Finland
Details to be announced
17:00 - 18:30 | Concurrent Sessions


Sponsored Session: BCPT Nordic Symposium - Translational methods in drug metabolism and toxicity
Chairs, Aleksi Tornio, University of Turku, Turku, Finland and Ulf Simonsen, Aarhus University, Aarhus, Denmark



17:00 - 17:30Use of an in vivo like hepatic 3D spheroid model to study drug metabolism, drug hepatotoxicity,
liver regeneration, hepatitis and MASH
Magnus Ingelman-Sundberg, Karolinska Institutet, Stockholm, Sweden



17:30 - 18:00Translational aspects of biomarkers in chemotherapy-induced peripheral neuropathy
Tore B. Stage, University of Southern Denmark, Odense, Denmark



18:00 -18:15Grapefruit juice inhibits CYP2B6, CYP2C9, CYP2C19 and CYP3A4 while lingonberry powder
does not affect major CYP enzymes in humans (Abstract O032)
Laura Aurinsalo, University of Helsinki and Helsinki University Hospital, Helsinki, Finland



18:15 - 18:30Non-targeted metabolomics for the identification of plasma metabolites associated with
breast cancer resistance protein function (Abstract O033)
Kreetta Hämäläinen, University of Helsinki, Helsinki, Finland



EASLDHILI & IUPHAR Session B7: Drug induced liver injury - Current topics
Chairs: Caroline Samer, University of Geneva, Geneva, Switzerland and M Isabel Lucena, University of Malaga, Malaga, Spain

17:00 - 17:30Pharmacogenomics in DILI: A pathway to personalized precision medicine 
Ann Daly, University of Newcastle, Newcastle, United Kingdom




17:30 - 18:00Design, endpoints and challenges in conducting randomized clinical trials in DILI
Yimin Mao, Shanghai Jiao Tong University, Shanghai, China




18:00 - 18:15Hepatic zonal distribution of OATP1B transporters and CYP enzymes affects simulated
intracellular unbound concentrations of repaglinide and coproporphyrin I (Abstract O034) 
Marie-Noëlle Paludetto, University of Manchester, Centre For Applied Pharmacokinetic
Research, Manchester, United Kingdom




18:15 - 18:30Liver-derived extracellular vesicles for multi-omics analysis of drug metabolism and liver
disease (Abstract O035)
Natalie Widmann, Dr. Margarete Fischer-bosch Institute Of Clinical Pharmacology,
Stuttgart, Germany




Education symposium 2 (Education Working Group) 
Chairs: Joost Piët, Amsterdam UMC, Amsterdam, the Netherlands 

17:00 - 17:30EU Project reporting - Speakers to be announced




17:30 - 18:30Clinical Pharmacology and Therapeutics Teach the Teacher (CP4T) workshop:
How to set up a student-assistant system for CPT education
Joost Piët


17:00 pm - 18:30 pm | EACPT Council Meeting (for Councillors only)
Chairs: EACPT Chairperson Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands and EACPT Chairperson-elect Janne Backman, University of Helsinki, Helsinki, Finland
18:30 pm - 19:30 pm | Free time
19:30 pm - | EACPT Congress Dinner at Restaurant Kalastajatorppa (separate ticket required)